IGFBP2 exhibits conflicting roles in cancer, acting as both an oncogene and a tumor suppressor depending on various influencing factors.
The role of insulin-like growth factor binding protein 2 (IGFBP2) in cancer is unclear. In general, IGFBP2 is considered to be oncogenic and its expression is often observed to be elevated in cancer. However, there are a number of conflicting reports in vitro and in vivo where IGFBP2 acts in a tumor suppressor manner. In this mini-review, we discuss the factors influencing the variation in IGFBP2 expression in cancer and our interpretation of these findings.
Pickard et al. (Fri,) conducted a review in Cancer. IGFBP2 was evaluated. IGFBP2 exhibits conflicting roles in cancer, acting as both an oncogene and a tumor suppressor depending on various influencing factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: